Afficher la notice abrégée

Liver fibrosis regression in people living with HIV after successful treatment for hepatitis C

dc.rights.licenseopenen_US
dc.contributor.authorYOUNG, Jim
dc.contributor.authorWANG, Shouao
dc.contributor.authorSACKS-DAVIS, Rachel
dc.contributor.authorSTEWART, Ashleigh
dc.contributor.authorVAN SANTEN, Daniela K
dc.contributor.authorVAN DER VALK, Marc
dc.contributor.authorDOYLE, Joseph S
dc.contributor.authorMATTHEWS, Gail
dc.contributor.authorBERENGUER, Juan
hal.structure.identifierStatistics In System biology and Translational Medicine [SISTM]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorWITTKOP, Linda
dc.contributor.authorLACOMBE, Karine
dc.contributor.authorRAUCH, Andri
dc.contributor.authorSTOOVE, Mark
dc.contributor.authorHELLARD, Margaret
dc.contributor.authorKLEIN, Marina B
dc.date.accessioned2025-04-11T09:23:19Z
dc.date.available2025-04-11T09:23:19Z
dc.date.issued2025-02-20
dc.identifier.issn1944-7884en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/206134
dc.description.abstractEnBACKGROUND: Successful treatment of hepatitis C virus (HCV) can lead to liver fibrosis regression. It is not known who will experience fibrosis regression or how quickly it will occur. METHODS: We modelled transient elastography (TE) measurements from 1470 HIV-HCV coinfected participants followed in cohorts contributing data to InCHEHC, an international collaboration. Participants were eligible if they had at least one TE measurement in the year prior to starting a successful direct acting antiviral treatment for HCV. This measurement was used to classify participants into one of three fibrosis subgroups. We analysed measurement sequences in each subgroup using a covariate adjusted generalised additive mixed model, with an adaptive spline representing changes in the mean measurement before, during and after treatment. RESULTS: Each fibrosis subgroup had a distinctly different response. Most participants with cirrhosis (F4, TE ≥14.6 KPa) prior to HCV treatment did not show meaningful fibrosis regression - almost 70% were predicted to remain above 12 KPa three years after treatment ended. Participants with significant fibrosis (F2-F3, TE ≥7.2 and <14.6KPa) showed appreciable regression in the first two years after treatment, falling on average to levels below 7.2 KPa. Those without fibrosis prior to treatment (F0-F1) did not progress. CONCLUSION: Most coinfected people with cirrhosis prior to HCV cure will remain cirrhotic. For those with significant fibrosis, regression can be expected within two years to levels not normally associated with an increased risk of endstage liver disease. A TE measurement two years after cure should give a reliable estimate of residual fibrosis.
dc.language.isoENen_US
dc.title.enLiver fibrosis regression in people living with HIV after successful treatment for hepatitis C
dc.title.alternativeJ Acquir Immune Defic Syndren_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1097/qai.0000000000003646en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed39972551en_US
bordeaux.journalJournal of Acquired Immune Deficiency Syndromes - JAIDSen_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.institutionINRIAen_US
bordeaux.teamSISTM_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-05030578
hal.version1
hal.date.transferred2025-04-11T09:23:22Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=Journal%20of%20Acquired%20Immune%20Deficiency%20Syndromes%20-%20JAIDS&amp;rft.date=2025-02-20&amp;rft.eissn=1944-7884&amp;rft.issn=1944-7884&amp;rft.au=YOUNG,%20Jim&amp;WANG,%20Shouao&amp;SACKS-DAVIS,%20Rachel&amp;STEWART,%20Ashleigh&amp;VAN%20SANTEN,%20Daniela%20K&amp;rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée